X4 Pharmaceuticals (XFOR) Non Operating Income (2017 - 2025)
X4 Pharmaceuticals posted quarterly Non Operating Income of -$2.3 million for Q3 2025, down 1133.63% year-on-year from $226000.0 in Q3 2024, and down 542.42% on a QoQ basis from $528000.0 in Q2 2025.
X4 Pharmaceuticals (XFOR) has 9 years of Non Operating Income data on file, last reported at -$2.3 million in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Income fell 1133.63% year-over-year to -$2.3 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (down 61.74% YoY), and the FY2025 full-year result was -$753000.0, down 326.81% from the prior year.
- Non Operating Income for Q3 2025 stood at -$2.3 million, down from $528000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $24.9 million in Q3 2023 and bottomed at -$29.9 million in Q2 2023.
- The 5-year median for Non Operating Income is -$74000.0 (2021), against an average of $1.1 million.
- The widest annual swing landed in 2023, when Non Operating Income plunged 4585.27%; it then soared 9194.29% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$1.1 million in 2021, then plunged by 226.98% to -$3.8 million in 2022, then jumped by 262.12% to $6.1 million in 2023, then tumbled by 88.51% to $700000.0 in 2024, then plunged by 433.71% to -$2.3 million in 2025.
- The last three Non Operating Income figures came in at -$2.3 million (Q3 2025), $528000.0 (Q2 2025), and $9.8 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.34 Mn |
| Jun 30, 2025 | 528,000.00 |
| Mar 31, 2025 | 9.76 Mn |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 19.75 Mn |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 6.09 Mn |
| Sep 30, 2023 | 24.94 Mn |
| Jun 30, 2023 | -29.89 Mn |
| Mar 31, 2023 | 123,000.00 |
| Dec 31, 2022 | -3.76 Mn |
| Sep 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | -638,000.00 |
| Mar 31, 2022 | -674,000.00 |
| Dec 31, 2021 | -1.15 Mn |
| Sep 30, 2021 | -74,000.00 |
| Jun 30, 2021 | -635,000.00 |
| Mar 31, 2021 | -734,000.00 |
| Dec 31, 2020 | 411,000.00 |
| Sep 30, 2020 | 228,000.00 |
| Jun 30, 2020 | -486,000.00 |
| Mar 31, 2020 | 41,000.00 |
| Dec 31, 2019 | -1.31 Mn |
| Sep 30, 2019 | 52,000.00 |
| Jun 30, 2019 | 584,000.00 |
| Mar 31, 2019 | -435,000.00 |
| Dec 31, 2018 | -3.23 Mn |
| Sep 30, 2018 | -57,000.00 |
| Jun 30, 2018 | 342,000.00 |
| Mar 31, 2018 | -1.26 Mn |
| Dec 31, 2017 | -57,000.00 |
| Sep 30, 2017 | 86,000.00 |
| Jun 30, 2017 | -61,000.00 |
| Mar 31, 2017 | -1,000.00 |